Experimental drug combo aims to tackle tough colorectal cancer

NCT ID NCT06699836

Ongoing Disease control Sponsor: CytoDyn, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 study tests whether adding leronlimab to standard chemotherapy and a targeted drug can shrink tumors or improve survival in people with a specific type of advanced colorectal cancer (MSS mCRC) that has not responded to prior treatments. About 66 adults will receive one of two doses of leronlimab alongside the standard regimen. The main goals are to see if the combination increases tumor response and is safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: leronlimab (PRO 140) combined with trifluridine/tipiracil and bevacizumab
What this could lead to: If successful, this could offer a new treatment option for people with a hard-to-treat form of advanced colorectal cancer that has stopped responding to other therapies.
What could go wrong: This is an early Phase 2 trial with only 66 participants, so results may not apply to everyone. The added benefit of leronlimab is unproven, and combination therapy may increase side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER (MCRC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC COLORECTAL CANCER (MCRC)

Contacts and locations

Locations

City of Hope Orange County Lennar Foundation Cancer Center

Irvine, California, 92618, United States
Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States
Georgetown University Medical Center

Washington D.C., District of Columbia, 20007, United States
Norton Cancer Institute, Brownsboro Hospital Campus

Louisville, Kentucky, 40241, United States
Pacific Hematology Oncology Associates

San Francisco, California, 94115, United States
Summit Cancer Center

Spokane, Washington, 99208, United States
University of Nebraska Medical Center

Omaha, Nebraska, 68198, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.